Valeant Pharmaceuticals International Inc said on Monday it would sell its Obagi Medical Products business for $190 million in cash, as part of the Canadian drugmaker’s efforts to cut down its debt.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
